How Does the FDA Approve a New Weight-Loss Drug? From Clinical Trials to a Decision
We talk a lot about medications being “in Phase 3,” “submitted to the FDA,” or “waiting for approval.” Those phrases sound simple, but they represent very different points in a process that usually takes years.
Because I have been following CagriSema and retatrutide closely, this feels like a good time to explain what those milestones actually mean—without turning it into a regulatory textbook.
First: a drug has to earn its way into larger trials
Before human trials, developers do laboratory and preclinical work. Phase 1 studies are generally small and focus heavily on safety, dose, and how a drug behaves in the body. Phase 2 expands the number of participants and starts answering whether the treatment appears to work, at what doses, and with what side-effect pattern.
Phase 3 is the big test. These are larger studies designed to provide the confirmatory evidence regulators need when deciding whether a medication’s benefits outweigh its risks for a particular use.
Then comes the application
For many traditional drugs, the U.S. application is called a New Drug Application, or NDA. Some products are reviewed through a Biologics License Application, or BLA. For most patients, the important point is the same: the sponsor is formally asking the FDA to review the full evidence package.
That package is much bigger than a trial abstract. It includes clinical results, safety information, manufacturing and quality information, proposed prescribing information, and analyses that help reviewers understand exactly who was studied and how the medication is intended to be used.
What happens after submission?
For an NDA, the FDA generally has 60 days after receiving the application to decide whether it is complete enough to file for substantive review. Filing is not approval—it means the full review can begin.
Under the FDA’s current PDUFA review framework, the goal for many standard original applications is generally about 10 months after filing; priority-review applications generally have a six-month goal after filing. Those are review goals, not guarantees, and they come after years of preclinical and clinical development.
Where CagriSema and retatrutide are right now
As of October 2026, CagriSema is already in FDA review. Novo Nordisk submitted its NDA in December 2025 and continues to say it expects a U.S. decision in the fourth quarter of 2026.
Retatrutide is one step earlier. Lilly has now reported positive results across five Phase 3 studies and says it plans to submit a BLA to the FDA in the first quarter of 2027 while it completes the manufacturing and quality package supporting the application.
That contrast is useful: CagriSema shows us what the review stage looks like, while retatrutide shows us the final stretch before submission.
Why I actually like following the process
The FDA timeline is not just paperwork happening after the science. It is where years of trial data, manufacturing work, statistics, labeling, and clinical questions are pulled together into one decision.
For patients following new weight-management treatments, understanding the milestones makes the headlines much easier to interpret. “Phase 3 result,” “FDA submission,” and “FDA decision” are three different moments—and right now, major obesity medications are sitting at each of them.
Comments